The first 60 days: Chondrosarcoma
Chondrosarcoma is a cancer of cartilage-forming cells in bone. It is nearly immune to chemotherapy and radiotherapy, so complete surgery is the treatment, with proton or carbon-ion beams for skull base and spine tumours that cannot be fully removed. Half of conventional tumours carry an IDH mutation, and the IDH1 blocker ivosidenib is in a phase 3 trial. Below, week by week, is what OnCo's record of Chondrosarcoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Atypical cartilaginous tumour of the limbs.
- RadiologistNamed in the standard of care for: Atypical cartilaginous tumour of the limbs.
- SurgeonNamed in the standard of care for: Atypical cartilaginous tumour of the limbs, Conventional grade 2 to 3, resectable, Skull base and spine, incompletely resectable, Dedifferentiated and mesenchymal.
- Medical oncologistNamed in the standard of care for: Atypical cartilaginous tumour of the limbs, Conventional grade 2 to 3, resectable, Skull base and spine, incompletely resectable, Dedifferentiated and mesenchymal and 1 more.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Atypical cartilaginous tumour of the limbs, Conventional grade 2 to 3, resectable, Skull base and spine, incompletely resectable.
- Palliative and supportive care teamNamed in the standard of care for: Dedifferentiated and mesenchymal.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Wide en bloc resection with limb-salvage or pelvic reconstruction in a bone sarcoma centre; radiotherapy only for positive margins.
Maximal safe surgery followed by high-dose proton or carbon-ion radiotherapy.
Intralesional curettage with local adjuvant, or observation of asymptomatic lesions; no chemotherapy or radiotherapy.
Surgery plus osteosarcoma-type (doxorubicin, cisplatin) or Ewing-type (doxorubicin, ifosfamide) chemotherapy, benefit uncertain.
Ivosidenib within the CHONQUER phase 3 trial or compassionate access; no approved systemic therapy.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example IDH1 or IDH2 mutation, Histological grade 1 to 3 and dedifferentiation, HEY1-NCOA2 fusion, COL2A1 mutations, Site), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Conventional central chondrosarcoma, grades 1 to 3, Atypical cartilaginous tumour, Peripheralchondrosarcoma arising in osteochondroma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Atypical cartilaginous tumour of the limbs
- For my situation (atypical cartilaginous tumour of the limbs), which of the standard options do you recommend and why?Guideline options include: Intralesional curettage with local adjuvant, or observation of asymptomatic lesions; no chemotherapy or radiotherapy.
Conventional grade 2 to 3, resectable
- For my situation (conventional grade 2 to 3, resectable), which of the standard options do you recommend and why?Guideline options include: Wide en bloc resection with limb-salvage or pelvic reconstruction in a bone sarcoma centre; radiotherapy only for positive margins.
Skull base and spine, incompletely resectable
- For my situation (skull base and spine, incompletely resectable), which of the standard options do you recommend and why?Guideline options include: Maximal safe surgery followed by high-dose proton or carbon-ion radiotherapy.
Dedifferentiated and mesenchymal
- For my situation (dedifferentiated and mesenchymal), which of the standard options do you recommend and why?Guideline options include: Surgery plus osteosarcoma-type (doxorubicin, cisplatin) or Ewing-type (doxorubicin, ifosfamide) chemotherapy, benefit uncertain.
- Am I a candidate for Doxorubicin, Cisplatin, Ifosfamide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced IDH1-mutant conventional
- For my situation (advanced idh1-mutant conventional), which of the standard options do you recommend and why?Guideline options include: Ivosidenib within the CHONQUER phase 3 trial or compassionate access; no approved systemic therapy.
- Am I a candidate for Ivosidenib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Any stage
- Are there clinical trials I could join, for example of Ivosidenib, Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen, IDH inhibitors, Carbon-ion therapy?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No systemic therapy has ever been proven to help”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Dedifferentiated chondrosarcoma kills most patients within two years”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Chondrosarcoma: the full pageChondrosarcoma is a cancer of cartilage-forming cells in bone. It is nearly immune to chemotherapy and radiotherapy, so complete surgery is the treatment, with proton or carbon-ion beams for skull base and spine tumours that cannot be fully removed. Half of conventional tumours carry an IDH mutation, and the IDH1 blocker ivosidenib is in a phase 3 trial.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.